Log In Get Started
Press Releases May 5, 2026 08:30 AM

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

CorMedix Therapeutics Announces Q1 2026 Financial Results Release and Corporate Update Conference Call

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CRMD

CorMedix Therapeutics, a U.S.-based biopharmaceutical company, will release its first quarter 2026 financial results on May 14, 2026, before market open. Along with the earnings release, the company will host a corporate update conference call to provide additional insights on its business and operations.

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CRMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CorMedix will report financial results for Q1 ended March 31, 2026, on May 14, 2026.
  • The company will hold a conference call to update investors and stakeholders on corporate developments.
  • CorMedix focuses on developing and commercializing therapeutic products for life-threatening conditions in institutional care settings in the U.S.
  • The healthcare and biopharmaceutical sectors are directly impacted by CorMedix's product development and commercialization efforts.

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 14, 2026, and will host a corporate update conference call at 8:30am Eastern Time.

Thursday, May 14th @ 8:30am ET
Domestic:1-844-676-2922International:1-412-634-6840Webcast:Webcast Link  

About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


Risks

  • Financial performance for the quarter may not meet investor expectations, impacting stock valuation.
  • Regulatory hurdles or delays in product approval could affect future commercial prospects.
  • Market competition within the biopharmaceutical sector may limit growth or market penetration opportunities.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026